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The 340B drug pricing program was creat-ed to improve access to outpatient medi-cations for low-income and underinsured 
or uninsured patients.1,2 
The program grants reduced pricing on 
biologics, FDA-approved prescription 
drugs, insulins, and some OTC drugs with 
a prescription.3 Originally, this program 
was limited to about 90 safety-net hospitals 
known as qualified “covered entities.” 
Through the passage of the Affordable Care 
Act, these entities expanded to include 
cancer centers, critical access hospitals, 
federally qualified health centers, rural 
referral centers, sole community hospitals, 
and other settings.3
The program has exponentially grown with 
the expansion of the definition of a covered 
entity and the change to allow multiple 
contract pharmacies. Still, there are debates 
about the program’s financial impact and 
whether the discounts are passed along to 
enough underinsured or uninsured patients.4 
The Health Resources and Services 
Administration predicted that covered 
entities saved $3.8 billion on outpatient 
drugs through the program in 2013 and 
estimated that covered entities applying the 
340B program reached more than $16 billion 
in 2016.5 Hospitals have claimed that they 
have expanded services and reduced overall 
costs to patients.6 However, the Centers for 
Medicare & Medicaid Services (CMS) has 
contended that financial gains for hospitals 
have not been associated with clear evidence 
of expanded care or lower mortality 
among patients.7,8   
In 2018, the US Department of Health 
& Human Services (HHS) amended the 
program by cutting Medicare Part B outpa-
tient drug payments to 340B hospitals by 
28.5%, seeking to close a gap between those 
prices and Medicare Part B payments.9 
Proposed amendments would further reduce 
the payment to certain covered entities by 
an estimated $1.6 billion.10 As a result, a 
lawsuit was filed by the American Hospital 
Association, the Association of American 
Medical Colleges, Eastern Maine Healthcare 
Systems, Fletcher Hospital, and Henry Ford 
Health System. 
The most recent decision was from the 
US Court of Appeals for the District of 
Columbia Circuit on July 31. The court 
decreed in favor of HHS, allowing the lower 
340B program reimbursement.9 Hospitals 
have continued to challenge the rule and 
have argued dire financial consequences 
resulting from this policy change that 
includes an increased impact on small 
community hospitals without a significant 
financial cushion.9,11 All covered entities, 
hospitals, and those affected by these cuts 
to the program should provide comments by 
October 5 on this new rule.12 
Additionally, on August 4, CMS recom-
mended a shift to the Medicare Hospital 
Outpatient Prospective Payment System 
methodology. If enacted, this change would 
mean that certain covered entities would 
have a change in reimbursement from the 
average sale price (ASP) plus 6% to ASP 
minus 28.7% for separately payable drugs 
or biologicals acquired through the 340B 
program. It was also requested to continue 
the Medicare payment policy of paying an 
ASP of 22.5% for 340B-acquired drugs for 
calendar year 2021 and subsequent years.10 
This would add to previous cuts to total an 
estimated $2 billion to $2.5 billion reduction 
of 340B-covered medications.12
If these proposed CMS changes are 
implemented, affected covered entities must 
be ready and understand the direct impact on 
the organization, which could be critical.13
Explanation and Next Steps
Facilities designated as disproportionate 
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share hospitals or rural referral centers will 
receive reduced payment for certain sepa-
rately payable drugs or biologicals specified 
by CMS purchased under the program and 
furnished to a Medicare beneficiary.13
When determining the organizational cost 
of maintaining the 340B program rules, 
consider the cost of any employees added, 
such as individuals to the revenue integrity 
area to monitor the program or a purchasing 
agent position. Alternatively, additional 
expenses could occur in the internal 
auditing department to maintain compliance 
with the program, as many organizations 
have used third-party consultants to conduct 
annual program audits and reviews.
Additionally, staff members must be 
trained in the program, increasing the cost, 
and administrative costs associated with 
the program include planning, audit and 
meeting preparation, audit review, and 
response. Some other items to consider 
are the potential loss of goodwill related 
to the public release of the 340B audit 
findings and the hardware and software 
needed to maintain the split billing program 
and contract pharmacy compliance. Those 
entities subject to the group purchasing 
prohibition will also have a cost increase based 
upon the requirement to purchase medica-
tions at the wholesale acquisition cost. 
Conclusion
Hospitals must take a systematic approach 
and undertake financial calculations 
to ensure a clear understanding of the 
program’s real cost. Many hospitals have 
financially struggled during the COVID-19 
pandemic and this reduction without a 
significant increase in outpatient payments 
(proposed just 6%) aggregate on handling 
and overhead costs14 adds another hurdle for 
these organizations.  
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